Women with isolated REM sleep behavior disorder (iRBD), an early sign of Parkinson’s disease, exhibit fewer signs of early brain deterioration than men of similar age and disease severity, a study showed. The study, which analyzed the brains of almost 700 people with iRBD and healthy controls, found that women…
Most molecular features in the human brain differ between samples obtained from living individuals and those collected after death, according to new findings from the Living Brain Project, a multiscale investigation from The Friedman Brain Institute in New York. This study, led by researchers at the Icahn School of…
People with Parkinson’s disease have an increased abundance of the oral bacteria Streptococcus mutans — typically found in the mouth and associated with cavities in the teeth — in their gut, according to a new study involving patients and a mouse model. Once established in the gut, these bacteria…
Irlab Therapeutics has announced new advancements for its three symptoms-targeting Parkinson’s disease drugs — medications designed to treat apathy, prevent falls, and reduce uncontrolled movements, known as dyskinesia, among people with the neurodegenerative disease. Before the year’s end, the company intends to launch a Phase 1b clinical trial…
More than half of people with Parkinson’s disease take nutritional supplements, a study found. Yet fewer than half discuss them with their doctors. Almost one in three Parkinson’s patients use other forms of complementary and alternative medicine (CAM) alongside their standard treatment, the study found. Both practices are more…
CND Life Sciences has been awarded a $3 million grant from the U.S. National Institutes of Health (NIH) to evaluate whether its skin test can predict the risk of Parkinson’s disease in people with essential tremor. The three-year Small Business Innovation Research grant will support a study aimed…
A Phase 2 clinical trial evaluating Avextra’s cannabis-based oral solution’s safety and efficacy in people with Parkinson’s disease and other neurodegenerative disorders has enrolled its first patient. The medicine used in the NEUROBIS (EUCT 2023-507715-35-02) clinical trial is described as a full-spectrum cannabis extract, meaning it contains…
Kneu Health said it has raised $5.6 million to expand its smartphone-based platform that helps doctors monitor symptoms of Parkinson’s disease and other neurological conditions. The company’s platform is a clinically validated tool that tracks changes in movement, speech, and thinking via smartphone. One of its features —…
Deep brain stimulation (DBS) can provide lasting relief from motor symptoms and help people with Parkinson’s disease function better day to day over time, while reducing the need for medication, according to a study led by University of Florida (UF) Health. The new study showed that improvements in…
A new trial platform that will test multiple disease-modifying treatments for Parkinson’s disease is now recruiting participants in the U.K., Cure Parkinson’s has announced. The program, called EJS ACT-PD, will initially test two therapies, telmisartan and terazosin, against a shared placebo. A third treatment, ursodeoxycholic acid, is expected…
Get regular updates to your inbox.
